Ben Wilkes, Igor Vatolkin, Heinrich Müller
Statistical and Visual Analysis of Audio, Text, and Image Features for Multi-Modal Music Genre Recognition
Entropy (Basel, Switzerland)
previous clinical trials established efficacy safety sucroseformulated recombinant factor f viii rfviiifskogenate fshelixate fs octocog alfa bay 818973kovaltry leopold trials report results post hoc subgroup analysis assessing efficacy safety outcomes patients hemophilia receiving rfviiifs prior enrolling leopold part b leopold kids part clinical trials switching octocog alfa leopold part b nct01029340 leopold kids part nct01311648 octocog alfa phase 3 multinational openlabel studies patients severe hemophilia aged 1265 years 12 years respectively annualized bleeding rate abr efficacy endpoint studies safety endpoints included adverse events aes development fviii inhibitors 113 patients leopold trials 40 354 patients received rfviiifs prophylaxis prestudy data available prestudy total abr leopold part b n 22 355 median q1 q3 total abr decreased 25 00 90 prestudy 10 00 68 10 00 60 prestudy 00 00 602 leopold kids part n 18 353 octocog alfa well tolerated patients drugrelated serious aes inhibitors treatment octocog alfa prophylaxis appeared favorable riskbenefit profile compared rfviiifs thus could effective improved alternative strategy individualized treatment children adolescent adult patients severe hemophilia currently rfviiifs treatment